Blog - Page 4057 of 5386

MondayNov 03, 2008 5:44 am

Synvista Therapeutics, Inc. (AMEX: SYI)

Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company's web site at www.alteon.com.

MondayNov 03, 2008 5:44 am

Cytokinetics, Incorporated (NASDAQ: CYTK)

Cytokinetics, Incorporated (NASDAQ: CYTK), a biopharmaceutical company, is devoted to the discovery, development and commercialization of innovative small molecule drugs. The company’s cardiovascular disease program is focused on cardiac myosin, which is a motor protein vital to cardiac muscle contraction. CK-1827452, Cytokinetics' lead compound from this program, is a small molecule cardiac myosin activator that has entered Phase II clinical trials for the treatment of heart failure. For further information, visit the Company's web site at www.cytokinetics.com.

MondayNov 03, 2008 5:44 am

Synta Pharmaceuticals Corp. (NASDAQ: SNTA)

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company, has dedicated their efforts to discovering, developing, and commercializing innovative pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. The company has an exceptional chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with innovative chemical structures and distinct mechanisms of action. For further information, visit the Company's web site at www.syntapharma.com.

MondayNov 03, 2008 5:43 am

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN)

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) is a Chinese company that is engaged in the manufacture and sale of a wide range of neutraceutical products. Sunwin’s product lines include zero-calorie all natural Stevia sweeteners, traditional Chinese medicines, as well as veterinary medicines and animal feeds prepared from 100% organic herbal ingredients. Sunwin has built an integrated global organization with the sourcing and production capabilities to satisfy the needs of global consumers. For further information, visit the company website at: www.sunwininternational.com.

MondayNov 03, 2008 5:43 am

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company's web site at www.cyclacel.com.

MondayNov 03, 2008 5:43 am

SuperGen, Inc. (NASDAQ: SUPG)

SuperGen, Inc. (NASDAQ: SUPG) is focused on building a global, sustainable business by developing and commercializing new drug candidates for oncologists, hematologists, and their patients. The company’s staff is made up of talented individuals who recognize the incredible challenges of drug development. Although some work along and other on teams, each employee brings a distinct perspective to his or her job and is focused on the goal of bringing better products to cancer patients in need. For further information, visit the Company's web site at www.sunesis.com.

MondayNov 03, 2008 5:43 am

CV Therapeutics, Inc.’s (NASDAQ: CVTX)

CV Therapeutics, Inc.’s (NASDAQ: CVTX) primary focused is on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. The company is devoted to discovering new solutions for the unmet medical needs of patients. By emphasizing on discovery science and small molecule therapeutics, the company’s drug candidates are usually able to be produced by conventional pharmaceutical manufacturing methods. For further information, visit the Company's web site at www.cvt.com.

MondayNov 03, 2008 5:42 am

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), an emerging biopharmaceutical company, has focused their efforts on creating new medicines designed to improve the lives of patients diagnosed with cancer. The company is currently building a pipeline of drugs that selectively block vital mechanisms necessary for tumor growth and survival. Sunesis recognizes that the fight against cancer is an enormous mission that requires an integrated approach and innovation. For further information, visit the Company's web site at www.sunesis.com.

MondayNov 03, 2008 5:42 am

Curis, Inc. (NASDAQ: CRIS)

Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company's web site at www.curis.com.

MondayNov 03, 2008 5:42 am

Stroud Resources Ltd. (TSX: SDR CN)

Stroud Resources Ltd. (TSX: SDR CN), an exploration company focused on the discovery and exploration of silver and gold deposits, is completely debt free and has yearly cash flow of approximately $200,000 from its 3.75% interest in six natural gas and gas condensate wells. Currently, the company has two gold properties in Ontario Canada, and two silver projects in Mexico. The Hislop gold project located in Timmins Ontario with indicated resources of 102,750 oz. and the Santo Domingo Silver project based in Mexico are both 100% owned by Stroud Resources. For further information, visit the Company's web site at www.stroudresourcesltd.com.

Site Search

Company Search

Synvista Therapeutics, Inc. (AMEX: SYI)

Cytokinetics, Incorporated (NASDAQ: CYTK)

Synta Pharmaceuticals Corp. (NASDAQ: SNTA)

Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)

SuperGen, Inc. (NASDAQ: SUPG)

CV Therapeutics, Inc.’s (NASDAQ: CVTX)

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)

Curis, Inc. (NASDAQ: CRIS)

Stroud Resources Ltd. (TSX: SDR CN)

Market Basics

Newsletter Publishers

Public Companies